# Locus Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/locus-biosciences

- Industry: Biotechnology
- Headquarters: Morrisville, US
- Website: www.locus-bio.com
- Total disclosed funding: $54M
- Latest round: Series B (May 18, 2022)
- Investors on record: 7

## About

Based in North Carolina, US, and founded in 2015 by CEO Paul Garofolo, Locus Biosciences, Inc. operates as a biopharmaceuticals research company that focuses on developing antibacterial products for antibiotic-resistant bacterial infections and microbiome-related diseases using CRISPR technology. In January 2024, Locus Biosciences, Inc. raised USD 23.9 million in grant funding from Biomedical Advanced Research and Development Authority. 

Locus Biosciences, Inc. integrates advanced technologies such as AI-directed automated robotics and synthetic biology to improve treatments in areas including immunology, oncology, and central nervous system (CNS) disorders. The company offers a variety of products such as LBP-EC01, LBP-PA01, LBP-SA01, LBP-KP01, and LBP-AIEC01. In addition, the firm specializes in development of engineered bacteriophage products to combat bacterial infections and leverage the microbiome to treat various diseases.

## Funding rounds

- Series B, May 18, 2022, $35M — Johnson & Johnson Innovation, Viking Global Investors, ARTIS Ventures, Tencent Investment, Discovery Innovations
- Series A, Nov 14, 2017, $19M — North Carolina Biotechnology Center, ARTIS Ventures, Tencent Investment, Abstract Ventures

## Investors

- North Carolina Biotechnology Center — Series A
- ARTIS Ventures (https://capitalatlas.ai/funds/artis-ventures) — Series A, Series B
- Tencent Investment — Series A, Series B
- Abstract Ventures (https://capitalatlas.ai/funds/abstract-ventures) — Series A
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series B
- Viking Global Investors (https://capitalatlas.ai/funds/viking-global-investors) — Series B
- Discovery Innovations — Series B